Immunai is pioneering the development of an advanced AI model of the immune system, aimed at enhancing the discovery and development of next-generation immunomodulatory therapeutics. The company employs a multi-faceted approach that integrates multi-omic single-cell analysis, machine learning, and functional genomics to address critical challenges in drug development. Their platform, AMICA™ (Annotated Multi-Omic Immune Cell Atlas), serves as a comprehensive knowledge base, encompassing extensive clinico-genomic data from millions of immune cells across various disease contexts. This rich dataset enables Immunai to prioritize clinical trial designs, validate therapeutic hypotheses, and identify potential biomarkers for patient stratification, ultimately accelerating the path to effective treatments.

The technology underpinning Immunai's platform includes deep, multi-omic single-cell profiling and a dynamic functional genomics framework that allows for multiplexed perturbations. By leveraging a vast array of curated public data and proprietary research, Immunai's integrated platform generates high-resolution insights that inform clinical decision-making. Their innovative approach also optimizes preclinical model systems to better reflect human physiology, thereby increasing the predictive power of drug efficacy and safety evaluations. This comprehensive strategy positions Immunai at the forefront of immunotherapy development, with the goal of delivering more effective and personalized treatment options for patients.

United States

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.

Immunai

Company Details